450 results on '"Poloni, Antonella"'
Search Results
2. Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms
3. A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure
4. Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience
5. MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells
6. Unveiling the genetic landscape of suspected congenital dyserythropoietic anemia type I: A retrospective cohort study of 36 patients
7. Bone Marrow Adipose Tissue
8. Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis
9. History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona
10. AL amyloidosis: an overview on diagnosis, staging system, and treatment.
11. Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium.
12. Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway
13. Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman–Diamond syndrome cells
14. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
15. Prescription patterns of venetoclax in acute myeloid leukemia.
16. The Time Has Come for Targeted Therapies for AML: Lights and Shadows
17. Feasibility and Outcome of a Phase II Study of Intensive Induction Chemotherapy in 91 Elderly Patients with AML Evaluated Using a Simplified Multidimensional Geriatric Assessment
18. Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations
19. Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort.
20. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
21. Ataluren improves myelopoiesis and neutrophil chemotaxis by restoring ribosome biogenesis and reducing p53 levels in Shwachman–Diamond syndrome cells.
22. S298: MATERNAL AND FETAL OUTCOMES IN PREGNANCIES OF WOMEN WITH IMMUNE THROMBOCYTOPENIA: A MULTICENTER RETROSPECTIVE OBSERVATIONAL ITP-NET ITALIAN STUDY
23. S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
24. PB2611: EVANS SYNDROME: DISEASE AWARENESS AND CLINICAL MANAGEMENT IN A NATION-WIDE ITALIAN SURVEY
25. Immunomodulatory Effects of Tyrosine Kinase Inhibitor In Vitro and In Vivo Study
26. Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study
27. The Time Has Come for Targeted Therapies for AML: Lights and Shadows
28. Mutations in the splicing factor SF3B1are linked to frequent emergence of HLA-DRlow/negmonocytes in lower-risk myelodysplastic neoplasms
29. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
30. Bone marrow adipose tissue is a unique adipose subtype with distinct roles in glucose homeostasis
31. Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study
32. Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
33. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
34. A rare case of aCML associated with CNS involvement and with aggressive clinical course
35. Molecular and Functional Characterization of Human Adipocytes
36. PB2670: EQOL‐MDS TRIAL: PATIENT‐REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.
37. Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
38. Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation
39. Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)
40. A 50 Hz magnetic field influences the viability of breast cancer cells 96 h after exposure
41. Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience
42. Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Treatment of Myeloproliferative Neoplasms in Blastic Phase (MPN-BP) and Acute Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine
43. Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin
44. ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems
45. Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
46. Telomere length, c-myc and mad-1 expression could represent prognosis markers of myelodysplastic syndrome
47. Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
48. Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications
49. Novel Translational Read-through–Inducing Drugs as a Therapeutic Option for Shwachman-Diamond Syndrome
50. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.